<!DOCTYPE html>
<html>
<head>
    <title>PressReader - The Straits Times: 2020-09-16 - Over 29,000 en&#xAD;rolled in Pfizer&#x2019;s Covid-19 trial</title>
    <meta name="description" content="">
    <meta content="magazines, newspapers, digital news, reading, news, breaking news, newspaper online" name="keywords">
    <meta name="Robots" content="NOARCHIVE,NOODP">
    <meta charset="UTF-8">
    <meta http-equiv="Content-type" content="text/html; charset=utf-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1" />
    
    <link rel="canonical" href="/singapore/the-straits-times/20200916/281805696349483" />


    <style>
        li {
            margin: 1em 0;
        }
        img {
            max-width: 100%;
        }
        p, h1, h2, h3 {
            max-width: 100%;
        }
    </style>
</head>
<body>
    <div>
        

<article>
    <h1>Over 29,000 en&#xAD;rolled in Pfizer&#x2019;s Covid-19 trial</h1>
    <h2></h2>
    <section>
        <a href="/singapore/the-straits-times/textview" title="The Straits Times">The Straits Times</a>
        - <a href="/singapore/the-straits-times/20200916/textview" title="The Straits Times - 2020-09-16"><time>2020-09-16</time></a>
        - <span>WORLD</span>
        - <span role="byline"></span>
    </section>

    <p>NEW YORK • Pfizer said on Mon­day it had en­rolled more than 29,000 peo­ple in its 44,000-vol­un­teer trial to test the ex­per­i­men­tal Covid-19 vac­cine it is de­vel­op­ing with Ger­man part­ner BioN­Tech.</p>
    <p>The Amer­i­can phar­ma­ceu­ti­cal cor­po­ra­tion ex­panded the size of the trial from 30,000 peo­ple over the weekend. It has said it could have re­sults next month on whether the vac­cine works.</p>
    <p>Fel­low US biotech­nol­ogy com­pany Moderna’s late-stage data and As­traZeneca’s ef­forts with the Univer­sity of Ox­ford are not far be­hind. As­traZeneca’s trial i n Britain has re­sumed after a pause of less than a week after a par­tic­i­pant fell ill.</p>
    <p>The tri­als will gauge how ef­fec­tive a vac­cine is based on in­fec­tion rates in those get­ting a placebo com­pared with those get­ting a shot and may pro­duce in­terim re­sults as soon as the first 30 or 40 peo­ple be­come in­fected.</p>
    <p>“It’s truly a num­bers game,” said an­a­lyst Yaron Wer­ber at Cowen & Co. He and a hand­ful of other Wall Street an­a­lysts view the Pfizer and BioN­Tech vac­cine as the most promis­ing so far.</p>
    <p>The tim­ing of a vac­cine has come un­der in­creas­ing scru­tiny as the United States pres­i­den­tial elec­tion nears and Pres­i­dent Don­ald Trump ap­pears to be pres­sur­ing the Food and Drug Ad­min­is­tra­tion for a shot, de­spite as­sur­ances from the agency as well as some drug­mak­ers that de­ci­sions will be based on sci­ence.</p>


</article>

<section>
    <h3><a href="/catalog/language/english">Newspapers in English</a></h3>
    <h3><a href="/catalog/country/singapore">Newspapers from Singapore</a></h3>
</section>

    </div>
    
    <p><a href="http://www.pressreader.com">© PressReader. All rights reserved.</a></p>

        <script>
            (function (i, s, o, g, r, a, m) {
                i['GoogleAnalyticsObject'] = r; i[r] = i[r] || function () {
                    (i[r].q = i[r].q || []).push(arguments);
                }, i[r].l = 1 * new Date();
                a = s.createElement(o), m = s.getElementsByTagName(o)[0]; a.async = 1; a.src = g;
                m.parentNode.insertBefore(a, m);
            })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
        </script>
        <script>
            ga('create', 'UA-44408245-1');
            ga('send', 'pageView');
        </script>
</body>
</html>
